A Single-Center Observational Biomarker Investigation of Response to Bacteriophage Treatment for Bacterial Infection
This study aims to identify biomarkers associated with response to phage therapy for refractory bacterial infections. Blood and leftover and/or discarded airway samples will be obtained from follow up visits of patients with refractory bacterial infections that are considered for phage therapy. Samples will be compared between those that receive phage therapy and those that did not. Biomarkers will include neutralizing antibody against phages, inflammatory cytokines, transcriptome and microbiome. The primary endpoint is to identify biomarkers associated with clinical and/or radiographic improvement and/or culture improvement which includes clearing of cultures or decrease in qualitative or resolution of signs and symptoms of infection after at least 6-8 weeks of bacteriophage therapy.
• Adults 18 years of age or older
• Provision of appropriate written consent
• Willingness and ability to participate in study procedures
• Diagnosis of bacterial infection that meets criteria for treatment (clinical, radiographic, and microbiologic data)
• Patients are being considered by clinician for phage therapy as a part of their standard of care